TC Biopharm (Holdings) PLC announced the formation of a scientific advisory board (SAB) to advance its gamma-delta T cell therapy, OmnImmune®, for the treatment of Acute Myeloid Leukemia (AML). Members of the TC BioPharm Scientific Advisory include; Mark Bonyhadi, Ph D., will lead the SAB. He is a senior advisor to Qiming Venture Partners USA and former Vice President of Research at Juno Therapeautics (acquired by Celgene).

Uma Lakshmipathy, Ph D., has two decades of experience in cell biology, stem cells and translational research. She is currently the Director of R&D in Science and Technology and Head of Patheon Translation Services in Pharma Services Group at Thermo Fisher Scientific. Erin Adams, Ph D., is the Joseph Regenstein Professor of Biochemistry and Molecular Biology at the University of Chicago and an expert in molecular immunology.

She explores the molecular cues that the human immune system uses to distinguish between healthy and diseased tissue.